Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
about
Recent advances of highly selective CDK4/6 inhibitors in breast cancerCDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer.Progress with palbociclib in breast cancer: latest evidence and clinical considerations.Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.CDK4/6 inhibitors sensitize Rb-positive sarcoma cells to Wee1 kinase inhibition through reversible cell cycle arrest.Cellular senescence in renal ageing and disease.Understanding cell cycle and cell death regulation provides novel weapons against human diseases.Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial.Synthesis and Anti-Proliferative Effects of Mono- and Bis-Purinomimetics Targeting Kinases.Recent advances of cyclin-dependent kinases as potential therapeutic targets in HR+/HER2- metastatic breast cancer: a focus on ribociclib.Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling.Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.Discovery and Pharmacological Characterisation of a Novel Series of Highly Selective Inhibitors of Cyclin-Dependent Kinases 4 and 6 as Anticancer Agents.Inhibition of cyclin-dependent kinase 4 as a potential therapeutic strategy for treatment of synovial sarcoma.MAPK reliance via acquired CDK4/6 inhibitor resistance in cancer.Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer.Recent Advances in the Treatment of Breast Cancer.Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and LiteratureTargeting the cell cycle in breast cancer: towards the next phaseA paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitorsCyclin-dependent kinase 4 is a preclinical target for diet-induced obesity
P2860
Q33602076-FAF3B05E-1B66-4E9F-944B-CAD23C28AA2CQ33614544-D0D598CA-3B4F-4352-A3D2-1D0DF0303DD3Q37632170-13F865DE-8100-4E2E-A52A-E9FB2648CFF4Q38649485-56958506-AD1B-457E-AF23-A0CE05AE37CFQ38662999-D86129AC-9863-4976-8AE6-E6B99313450FQ38723383-DB65DCE0-7ECE-4404-B227-B1FE985070D1Q39060497-956D8944-FCE9-49D9-96A7-EFA22F2D5D1EQ39218376-4032E003-2958-4AFF-9F2A-51907B2054E4Q41551635-2560888E-CC96-4ED1-819C-216EFB654DB2Q47161171-65D1F12C-66B4-4ED7-9303-040A0CF28883Q47169141-581ECF96-C5F5-4F98-8BAD-4E4DD5461B03Q47406875-D2C650ED-45C5-4FA8-85A2-4B9BB9D156D8Q47551153-85EBA972-2AF5-4215-A289-26DAC74A6A32Q47963513-85A623AA-26AA-41F4-8595-C0A5E56DA2CBQ52579552-0FE1DB90-50E6-4F96-92E3-6B49EA8CA5FDQ53685801-AEB072CE-4A4D-47F3-87E2-BA6BDDC6C68BQ55310990-D3B25B4B-88C5-4B31-937F-734AA5BC7C72Q55353691-581828A2-5A12-4325-B6C9-F0D325FA8221Q57108908-F393ACD7-8709-4304-AFCF-380FB817AA61Q57115037-D5B2A475-A3A1-451C-B5BC-928CE11FB307Q58700136-FCAF6C7D-20E3-466D-A829-17BDB21ED2CBQ58760731-A78D6644-14FE-480F-AE17-9DF4F5DCF140
P2860
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
@ast
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
@en
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
@nl
type
label
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
@ast
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
@en
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
@nl
prefLabel
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
@ast
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
@en
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
@nl
P2860
P356
P1433
P1476
Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer
@en
P2093
Geoffrey I Shapiro
Sara M Tolaney
P2860
P304
P356
10.1159/000447284
P407
P577
2016-06-22T00:00:00Z